Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anacetrapib add-on to statin therapy in hypercholesterolemia or low HDL-C
NL-OMON40028Phase 3Active, not recruiting
- Sponsor
- Merck & Co.
- Start
- Jun 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of anacetrapib in hypercholesterolemia and Hypo-HDL cholesterolemia (HALP) (3 arms), sponsored by Merck & Co. Primary endpoints: Percent change from baseline in LDL-C at Week 24, Percent change from baseline in HDL-C at Week 24 and 1 more. Started Jun 2013; status: active, not recruiting.
02
Drugs
anacetrapib
03
Conditions
hypercholesterolemiaHypo-HDL cholesterolemia (HALP)
Beyond the preview
Go deeper on NL-OMON40028.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON40028.